You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海正藥業(600267.SH):注射用鹽酸吉西他濱及比卡魯胺片擬中標擬中標第五批全國藥品集採
格隆匯 06-23 19:11

格隆匯6月23日丨海正藥業(600267.SH)公佈,2021年6月23日,公司及全資子公司瀚暉製藥有限公司(“瀚暉製藥”)參加了聯合採購辦公室組織的第五批全國藥品集中採購的投標工作。

經聯採辦開標、評標後,公司產品注射用鹽酸吉西他濱、比卡魯胺片擬中標此次集中採購,並且公司根據各省市場潛力進行了省份遴選,中選結果公示3天后正式發佈。

注射用鹽酸吉西他濱(0.2g)的擬中標價格為64.00元/盒,比卡魯胺片(50mg)的擬中標價格為193.00元/盒。

公司的注射用鹽酸吉西他濱、比卡魯胺片均已通過仿製藥質量和療效一致性評價,分別於2021年2月和2021年3月收到國家藥品監督管理局核准簽發的《藥品補充申請批件》(詳見公吿編號:“臨2021-14號”和“臨2021-20號”)。公司比卡魯胺片2020年度以及2021年1-3月銷售收入分別為2,861萬元和818萬元,注射用鹽酸吉西他濱近三年基本未形成市場銷售規模。

次藥品集中採購是國家組織的第五批國家藥品集中採購,在執行上要求全國醫療機構優先使用集中採購中選品種,並確保完成約定採購量。此次公司擬中選價格與原銷售價格相比有一定程度下降。公司此次擬中選的品種若確定中選、簽訂購銷合同並實施後,將有利於上述產品快速打開國內銷售市場,提高市場佔有率,促進公司製劑業務的進一步發展,提升公司的品牌影響力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account